v3.26.1
Condensed Consolidated Statements of Equity (Deficit) (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Common stock
Treasury Stock, Common
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Noncontrolling interest
Beginning balance at Dec. 31, 2024 $ 3,364 $ 18 $ (8,201) $ 21,333 $ (7,900) $ (1,925) $ 39
Beginning balance (in shares) at Dec. 31, 2024   1,765          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net earnings attributable to AbbVie Inc. 2,224 $ 0 0 0 2,224 0 0
Other comprehensive income (loss), net of tax 387 0 0 0 0 387 0
Dividends declared (5,827) 0 0 0 (5,827) 0 0
Purchases of treasury stock (973) $ 0 (973) 0 0 0 0
Purchases of treasury stock (in shares)   (5)          
Stock-based compensation plans and other 681 $ 0 27 654 0 0 0
Stock-based compensation plans and other (in shares)   6          
Change in noncontrolling interest 6 $ 0 0 0 0 0 6
Ending balance at Jun. 30, 2025 (138) $ 18 (9,147) 21,987 (11,503) (1,538) 45
Ending balance (in shares) at Jun. 30, 2025   1,766          
Beginning balance at Mar. 31, 2025 1,462 $ 18 (9,137) 21,808 (9,527) (1,742) 42
Beginning balance (in shares) at Mar. 31, 2025   1,766          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net earnings attributable to AbbVie Inc. 938 $ 0 0 0 938 0 0
Other comprehensive income (loss), net of tax 204 0 0 0 0 204 0
Dividends declared (2,914) 0 0 0 (2,914) 0 0
Purchases of treasury stock (10) $ 0 (10) 0 0 0 0
Purchases of treasury stock (in shares)   0          
Stock-based compensation plans and other 179 $ 0 0 179 0 0 0
Stock-based compensation plans and other (in shares)   0          
Change in noncontrolling interest 3 $ 0 0 0 0 0 3
Ending balance at Jun. 30, 2025 (138) $ 18 (9,147) 21,987 (11,503) (1,538) 45
Ending balance (in shares) at Jun. 30, 2025   1,766          
Beginning balance at Dec. 31, 2025 (3,228) $ 18 (9,146) 22,495 (15,493) (1,144) 42
Beginning balance (in shares) at Dec. 31, 2025   1,768          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net earnings attributable to AbbVie Inc. 4,308 $ 0 0 0 4,308 0 0
Other comprehensive income (loss), net of tax (14) 0 0 0 0 (14) 0
Dividends declared (6,148) 0 0 0 (6,148) 0 0
Purchases of treasury stock (1,498) $ 0 (1,498) 0 0 0 0
Purchases of treasury stock (in shares)   (6)          
Stock-based compensation plans and other 687 $ 0 26 661 0 0 0
Stock-based compensation plans and other (in shares)   5          
Change in noncontrolling interest 5 $ 0 0 0 0 0 5
Ending balance at Jun. 30, 2026 (5,888) $ 18 (10,618) 23,156 (17,333) (1,158) 47
Ending balance (in shares) at Jun. 30, 2026   1,767          
Beginning balance at Mar. 31, 2026 (6,612) $ 18 (10,611) 22,962 (17,872) (1,153) 44
Beginning balance (in shares) at Mar. 31, 2026   1,767          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net earnings attributable to AbbVie Inc. 3,613 $ 0 0 0 3,613 0 0
Other comprehensive income (loss), net of tax (5) 0 0 0 0 (5) 0
Dividends declared (3,074) 0 0 0 (3,074) 0 0
Purchases of treasury stock (9) $ 0 (9) 0 0 0 0
Purchases of treasury stock (in shares)   0          
Stock-based compensation plans and other 196 $ 0 2 194 0 0 0
Stock-based compensation plans and other (in shares)   0          
Change in noncontrolling interest 3 $ 0 0 0 0 0 3
Ending balance at Jun. 30, 2026 $ (5,888) $ 18 $ (10,618) $ 23,156 $ (17,333) $ (1,158) $ 47
Ending balance (in shares) at Jun. 30, 2026   1,767